Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.

Détails bibliographiques
Auteurs principaux:	Potter, M, Grace, S, Teehan, C, Ethell, M, Theocharous, P, Claude, R, Hale, G, Waldmann, H, Prentice, H
Format:	Journal article
Publié:	2000

Documents similaires

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
par: Novitzky, N, et autres
Publié: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
par: Kottaridis, P, et autres
Publié: (2001)

Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation
par: Martin eSzyska, et autres
Publié: (2016-03-01)

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation
par: Mauro Di Ianni, et autres
Publié: (2024-01-01)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
par: Raffaella Greco, et autres
Publié: (2019-10-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
par: Fibbe, W, et autres
Publié: (1993)

The Role of Bacteria and Pattern Recognition Receptors in GvHD
par: E. Holler, et autres
Publié: (2010-01-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
par: Hale, G, et autres
Publié: (1988)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
par: Hemn Mohammadpour, et autres
Publié: (2023-03-01)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
par: Hale, G, et autres
Publié: (1996)

In marrow aplasia reduced-intensity conditioning and T-cell depletion of cytokine mobilised stem cells provides good engraftment without GvHD
par: Novitzky, N, et autres
Publié: (2006)

Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD
par: Jongbok Lee, et autres
Publié: (2025-01-01)

Modulation of T-regulatory cells by small molecules: potential therapy for GvHD
par: Leuschner, U
Publié: (2021)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
par: Kudakwashe Mhandire, et autres
Publié: (2021-10-01)

Effective Extracorporeal Photopheresis of Patients with Transplantation Induced Acute Intestinal GvHD and Bronchiolitis Obliterans Syndrome
par: Robin Reschke, et autres
Publié: (2022-08-01)

The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: A historical overview.
par: Margherita Boieri, et autres
Publié: (2016-08-01)

Effect of the YCD3-1 Anti-Mouse Monoclonal on Murine GvHD
par: James P. Okunewick, et autres
Publié: (1993-07-01)

Quality of life of patients with graft-versus-host disease (GvHD) post-hematopoietic stem cell transplantation
par: Sibéli de Fátima Ferraz Simão Proença, et autres

The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD following Hematopoietic Stem Cell Transplantation
par: Seyed Asadollah Mousavi, et autres
Publié: (2016-12-01)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
par: Chakrabarti, S, et autres
Publié: (2004)

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
par: Ines Bojanic, et autres
Publié: (2023-02-01)

Antigen-specific priming is dispensable in depletion of apoptosis-sensitive T cells for GvHD prophylaxis
par: Shai eYarkoni, et autres
Publié: (2014-05-01)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
par: Novitzky, N, et autres
Publié: (2004)

HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis
par: Hiroko Shike, et autres
Publié: (2024-12-01)

INVITRO TREATMENT OF MARROW WITH ATCG OR CAMPATH-1 FOR PROPHYLAXIS OF GVHD - RESULTS OF THE AG-KMT MUNCHEN
par: Kolb, H, et autres
Publié: (1985)

Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival
par: Lambros Kordelas, et autres
Publié: (2021-09-01)

CAMPATH-1 antibodies in stem-cell transplantation.
par: Hale, G, et autres
Publié: (2001)

Availability of Campath-1 antibodies for bone marrow transplantation.
par: Hale, G, et autres
Publié: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
par: Hale, G, et autres
Publié: (1994)

HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis
par: Massimo Berger, et autres
Publié: (2022-02-01)

Spontaneous xenogeneic GvHD in Wilms' tumor Patient‐Derived xenograft models and potential solutions
par: Seyed Mostafa Monzavi, et autres
Publié: (2022-08-01)

Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
par: Roberto Crocchiolo, et autres
Publié: (2021-03-01)

Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy
par: Regina Jitschin, et autres
Publié: (2023-03-01)

Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD
par: Weijia Zhao, et autres
Publié: (2023-08-01)

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells
par: Haroon Shaikh, et autres
Publié: (2022-11-01)

FTY720 ameliorates GvHD by blocking T lymphocyte migration to target organs and by skin fibrosis inhibition
par: Jaeyoon Ryu, et autres
Publié: (2020-06-01)

3120 Probable multifocal central nervous system graft-versus-host disease (CNS GvHD) with concurrent cerebellitis following allogenic stem-cell transplant (ASCT) for T-cell leukemia
par: Deepti Dr Yagnik
Publié: (2024-08-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
par: Russell, N, et autres
Publié: (1999)

Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation.
par: Meng Lv, et autres
Publié: (2013-01-01)

CAMPATH: from concept to clinic.
par: Waldmann, H, et autres
Publié: (2005)